NorthWest Biotherapeutics Inc (NWBO)

[Pyrrhonian]

I try not to tempt the gods, but ya know ;). I think Adaptive Licensing (the CEO's specific mention) is a very real possibility for Direct, especially once a complete safety assessment on all 36 Ph I enrollees has been completed (6 months after last enrollee). They need a little more than preclinical results to get it, it would seem. A green light on safety with some semi mature and mature ORR data might do it. However, it is less probable than waiting until this Ph I/II has mature ORR data on the 24 (18 months after last enrollee), which might be as late as summer 2016. Of course, they may begin enrolling a seamless Ph II/III somewhere in there. Hard to say what might happen... Also hard to know where to place expectations. Breakthrough Therapy designation could be granted after Ph I/II results too.

I'll remain cautiously optimistic and not expect too much too soon.